8-K: Karyopharm Announces Preliminary 2024 Revenue and Outlines 2025 Objectives, Including Key Myelofibrosis Trial Data

Karyopharm Therapeutics reported preliminary 2024 revenue figures and detailed its 2025 objectives, with a focus on the Phase 3 SENTRY trial for myelofibrosis.

Summary

• Karyopharm Therapeutics announced preliminary unaudited full year 2024 total revenue of approximately $145 million and U.S. XPOVIO net product revenue of approximately $113 million.
• The company's top strategic objective for 2025 is to deliver top-line results from the Phase 3 SENTRY trial for myelofibrosis, expected in the second half of the year.
• Enrollment in the Phase 3 SENTRY trial is on track to be completed in the first half of 2025.
• The Phase 3 SENTRY trial is evaluating selinexor in combination with ruxolitinib in patients with JAK inhibitor-naive myelofibrosis.
• The company expects its current cash, cash equivalents, and investments to fund operations into the first quarter of 2026, excluding certain debt repayments.
• The company expects its cash, cash equivalents and investments will be sufficient to fund its operations into the fourth quarter of 2025, taking into account the repayment of the 2025 Notes and the minimum liquidity covenant.
• Karyopharm is also focused on maintaining its commercial presence in multiple myeloma and expanding global access for selinexor.
• The company is engaged with the FDA regarding the evolving treatment landscape in endometrial cancer and will provide an update on its program in the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with key clinical trial milestones on track and revenue figures in line with expectations. However, there are some challenges related to competition and gross-to-net adjustments.

Positives

• The company expects to deliver meaningful reductions in selling, general and administrative expense in 2024.
• The company has expanded global patient access for selinexor with favorable reimbursement decisions in multiple countries.
• The company completed significant refinancing transactions and amended a royalty agreement, extending debt maturities into 2028 and 2029.
• KPT-9274 received two Rare Pediatric Disease Designations and two Orphan Drug Designations from the FDA.
• The company reacquired KPT-350 and other assets from Biogen in February 2024.

Negatives

• XPOVIO net product revenue was impacted year-over-year by higher gross-to-net adjustments in 2024, driven primarily by increased 340B discounts and Medicare rebates.
• Demand for XPOVIO declined in the first half of 2024 due to an intensified competitive landscape.
• The company is engaged with the FDA regarding the evolving treatment landscape in endometrial cancer and any implications this may have with respect to the Company's Phase 3 XPORT-EC-042 trial.

Risks

• The company faces risks related to the commercialization of XPOVIO and the clinical development of its drug candidates.
• There are risks associated with regulatory approvals and the timing of decisions made by regulatory authorities.
• The company's financial performance could be affected by the adoption of XPOVIO in the commercial marketplace.
• The company's ability to continue as a going concern is subject to substantial doubt.
• The company faces competition from other companies developing similar products.
• The company's operations could be impacted by the COVID-19 pandemic or any future pandemic.
• The company's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates is a risk.

Future Outlook

Karyopharm expects to deliver top-line results from the Phase 3 SENTRY trial in the second half of 2025 and to continue global launches and reimbursement approvals for selinexor. The company also expects its current cash to fund operations into the first quarter of 2026, excluding certain debt repayments.

Management Comments

• Our top strategic objective for 2025 is to deliver on the transformative opportunity to redefine the standard of care in myelofibrosis, with top-line results from our Phase 3 SENTRY trial on-track for the second half of this year, said Richard Paulson, President and Chief Executive Officer of Karyopharm.
• We are excited by the potential for selinexor to be the first all-oral combination therapy in myelofibrosis and the benefit it may bring to this community.

Industry Context

The announcement highlights Karyopharm's focus on myelofibrosis, a space with significant unmet need, and its efforts to expand the use of selinexor in multiple cancer indications. The company is also navigating a competitive landscape in multiple myeloma, while seeking to expand global access for its products.

Comparison to Industry Standards

• The Phase 3 MANIFEST trial showed that less than half of patients achieved SVR35 and an Abs-TSS improvement of 11 to 14 points with ruxolitinib monotherapy, while Karyopharm's Phase 1 trial showed 79% of patients achieved SVR35 and an average Abs-TSS improvement of 18.5 points with selinexor plus ruxolitinib.
• The Phase 3 TRANSFORM-1 trial also showed less than half of patients achieved SVR35 and an Abs-TSS improvement of 11 to 14 points with ruxolitinib monotherapy, while Karyopharm's Phase 1 trial showed 79% of patients achieved SVR35 and an average Abs-TSS improvement of 18.5 points with selinexor plus ruxolitinib.
• The company is competing with other pharmaceutical companies in the multiple myeloma space, such as Johnson & Johnson, Bristol Myers Squibb, and Amgen, who have established therapies in this area.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the revenue figures, clinical trial progress, and the company's cash runway.
• Employees will be impacted by the company's focus on research and development and cost optimization.
• Patients will be impacted by the potential for new treatment options for myelofibrosis, multiple myeloma, and endometrial cancer.
• Partners will be interested in the company's progress in global launches and reimbursement approvals for selinexor.

Next Steps

• Complete enrollment of the Phase 3 SENTRY trial in the first half of 2025.
• Report preliminary data on a subset of participants in the Phase 2 SENTRY-2 trial in the first half of 2025.
• Report topline results from the Phase 3 SENTRY trial in the second half of 2025.
• Continue global launches and reimbursement approvals for selinexor by partners in ex-U.S. territories.
• Provide an update on the endometrial cancer program in the first quarter of 2025.
• Continue to follow patients that are enrolled in the Phase 3 XPORT-MM-031 (EMN29) trial.

Key Dates

Keywords

selinexor, XPOVIO, myelofibrosis, multiple myeloma, endometrial cancer, SENTRY trial, Karyopharm, revenue, clinical trials, FDA, XPO1 inhibitor